Dyslipidaemia Flashcards
Pathophysiology
Dyslipidaemia
Imbalance of lipids such as cholesterol, low-density lipoprotein cholesterol, (LDL-C), triglycerides, and high-density lipoprotein (HDL). This condition can result from diet, tobacco exposure, or genetic and can lead to cardiovascular disease with severe complications.
HDL VS LDL
HDL is high density lipoprotein = Hero found in health arteries
LDL is low density lipoprotein = Loser causes plaque buildup
What are triglycerides?
Type of fat in the body, in combination with high LDL leads to clogged arteries
Signs and symptoms
Dyslipidaemia
- Chest pains or tightness
- Dizziness
- Heart palpitations
- Exhaustion
- Trouble breathing
- Cold sweats
Drug rationale
Dyslipidaemia
Reduce progression of atherosclerosis, reduce risk of MI and stroke in patients with established CV disease, and improve survival.
Reduce premature CV morbidity and mortality in people at high risk of CV events.
Prevent pancreatitis due to hypertriglyceridaemia.
Drug treatment
Dyslipidaemia
- Statin
- If statin not tolerated ezetimibe, PCSK9 inhibitors
- Pt with High Cardiovascular risk = Statin + (2) OR Fibrate
Indication
Ezetimibe
- Treat high blood cholesterol
- Dyslipidaemia
MOA
Ezetimibe
Selectively inhibiting the absorption of cholesterol and phytosterol by the small intestine without altering the absorption of fat-soluble vitamins and nutrients.
Contraindications
Ezetimibe
- Liver problems
- Acute inflammation of the pancreas
- Severe renal impairment
- Abnormal liver function tests
- Rhabdomyolysis
Adverse effects
Ezetimibe
- Headache
- Diarrhoea
HMG-CoA reductase inhibitors also known as…
Statins
MOA: HMG-CoA reductase inhibitors / Statin
Drugs for Dyslipidaemia
* Inhibit HMG-CoA reductase
* increase hepatic cholesterol uptake
* reduce cholesterol, LDL
* small increase in HDL
Competitively inhibit 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase (a rate-limiting enzyme in cholesterol synthesis). Increase hepatic cholesterol uptake from blood, reduce concentrations of total cholesterol, LDL and triglyceride (modest), and produce a small increase in HDL concentrations.
Indication: Statin / HMG-CoA reductase inhibitor
- Hypercholesterolaemia
- High risk of coronary heart disease, with or without hypercholesterolaemia
Used in low doses for primary CVD prevention (high risk CVD patients with no pt Hx of CVD yet)
Used in high doses for secondary prevention of CVD (pt with recent CVD Hx)
Adverse reactions
Statins / HMG-CoA reductase inhibitor
- mild GI symptoms
- headache
- sleep disturbance
- dizziness
Muscle symptoms (myalgia, myopathy, rhabdomyolysis)
Risk of myopathy (with or without CK elevation) and rhabdomyolysis is dose-related. Risk is also increased by age, illness (see Precautions) and certain drug interactions (see Statins).
Muscle symptoms are more likely in the first 4–6 weeks after starting or increasing the dose of a statin. Statin-associated muscle symptoms are often difficult to differentiate from other causes; for further information see www.nps.org.au/sams.
There have been very rare reports of an autoimmune necrotising myopathy, generally with CK concentration >10 times ULN and anti-HMG-CoA reductase autoantibodies, which does not resolve solely on stopping the statin.
An effect on ocular muscles may cause visual disturbances (eg diplopia or blurred vision).
Aminotransferase concentrations
Elevated aminotransferases occur in 0.5–2% of patients treated with statins; it is dose-dependent, generally responds to a reduction in dosage.
Diabetes
Statins are associated with a slightly increased risk for new-onset diabetes which appears highest in those who are already more likely to develop diabetes.
A meta-analysis reported that, on average, treating 255 patients with statins for 4 years resulted in 1 additional case of diabetes (while possibly preventing >5 major coronary events).
Practice points
Statins / HMG-CoA reductase inhibitor
- do not stop if symptoms of ACS
- 1st choice for hypercholesterolaemia
- TIMING : simvastatin better at night, must be taken consistently
- Monitor Creatine (affects muscle issues)
Drug Class
Atorvastatin
Statin / HMG-CoA reductase inhibitor